NCT00310687

Persistence of Immune Response After Vaccination With MCC

A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,244 (planned)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 11 Years – 20 Years
• Healthy volunteers: Accepted

Summary

Persistence of Immune response after vaccination with MCC

Conditions

• Prevention of Meningococcal Infection

Interventions

Type	Name	Description
PROCEDURE	BLOOD DRAW

Timeline

• Start date: 2004-10-01
• Primary completion: 2005-12-01
• Completion: 2005-12-01
• First posted: 2006-04-04
• Last updated: 2014-09-19

Locations

1 site across 1 country: United Kingdom